Literature DB >> 8915502

Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system.

Y Takakura1, R I Mahato, M Yoshida, T Kanamaru, M Hashida.   

Abstract

The objective of this study was to examine the hepatic disposition characteristics of 20-mer model phosphodiester oligonucleotide (PO) and its partially phosphorothioated (PS3) and fully phosphorothioated (PS) derivatives in the single-pass isolated rat liver perfusion system. [32P]-labeled oligonucleotides were momentarily introduced into this system through the portal vein as a bolus input mode, and the venous outflow patterns were evaluated using statistical moment analysis. The apparent volumes of distribution of these oligonucleotides were greater than those of reference substances for vascular space (erythrocytes) and extracellular space (human serum albumin), indicating a significant interaction between oligonucleotides and the liver. Significant hepatic uptake of oligonucleotides was also observed. About 20%, 36%, and 52% of the injected dose (3 micrograms/rat) was taken up by the liver during a single passage after bolus injection of PO, PS3, and PS, respectively. In the case of PS injection, slow efflux from the liver was observed in the latter phase of perfusion. This suggests that the hepatic uptake process of these oligonucleotides greatly depended on their types. The results of collagenase perfusion experiments suggest that PS3 oligonucleotides were taken up by both liver parenchymal and nonparenchymal cells. The amount of total recovery in the liver decreased substantially by coadministration of polyinosinic acid, dextran sulfate, polycytidic acid and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid. This suggests that PS3 was taken up by the liver as an anionic molecule in a nonspecific manner.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915502     DOI: 10.1089/oli.1.1996.6.177

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  8 in total

Review 1.  Translational study of microRNAs and its application in kidney disease and hypertension research.

Authors:  Alison J Kriegel; Domagoj Mladinov; Mingyu Liang
Journal:  Clin Sci (Lond)       Date:  2012-05-01       Impact factor: 6.124

Review 2.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

3.  Receptor-mediated hepatic uptake of M6P-BSA-conjugated triplex-forming oligonucleotides in rats.

Authors:  Zhaoyang Ye; Kun Cheng; Ramareddy V Guntaka; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2006 May-Jun       Impact factor: 4.774

Review 4.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

5.  HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells.

Authors:  Ningning Yang; Zhaoyang Ye; Feng Li; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

6.  Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption.

Authors:  Manoe J Janssen; Tom T G Nieskens; Tessa A M Steevels; Pedro Caetano-Pinto; Dirk den Braanker; Melissa Mulder; Yolanda Ponstein; Shaun Jones; Rosalinde Masereeuw; Cathaline den Besten; Martijn J Wilmer
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-06       Impact factor: 8.886

7.  A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression.

Authors:  Daniel Meraviglia-Crivelli; Helena Villanueva; Ashwathi Puravankara Menon; Angelina Zheleva; Beatriz Moreno; María Villalba-Esparza; Fernando Pastor
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183

8.  Gene transfection of primary mouse hepatocytes in 384-well plates.

Authors:  Raghu Ramanathan; Nathan A Delvaux; Kevin G Rice
Journal:  Anal Biochem       Date:  2020-09-07       Impact factor: 3.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.